secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0000950170-24-071913
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders elect directors with majority support; Nasdaq confirms audit committee compliance
--------------------------------------------------------------------------------

- Peter Neupert elected with 69.15% for (30.85% withhold); Michelle Griffin with 82.93% for.
- Advisory vote on 2023 executive compensation passed with 86% support.
- Ratification of Ernst & Young as independent auditor for FY2024 passed with 99.6% approval.
- Nasdaq confirmed compliance with Listing Rule 5605(c)(2) after Peter Neupert joined audit committee in July 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024071913/0000950170-24-071913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024071913/adpt-20240607.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-071913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer